Patents by Inventor Arnon Rosenthal

Arnon Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME
    Publication number: 20160096884
    Abstract: Antibodies directed to the C-terminal side of ?-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Inventors: Arnon ROSENTHAL, Jaume PONS, Wei-Hsien HO
  • ANTI-COMPLEMENT FACTOR C1S ANTIBODIES AND USES THEREOF
    Publication number: 20160090425
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-C1s monoclonal antibodies. The invention further relates to the use of such anti-C1s antibodies in the detection of complement factors of the classical complement activation pathway, such as C1s. Additionally, the antibodies of this disclosure are useful for the diagnosis and treatment of disorders associated with an increased activation of the classical complement pathway, in particular autoimmune disorders and neurodegenerative diseases, including neurodegenerative diseases with synapse loss, such as Alzheimer's Disease. Methods of treatment of autoimmune and neurodegenerative diseases are also provided.
    Type: Application
    Filed: May 15, 2014
    Publication date: March 31, 2016
    Inventors: Arnon Rosenthal, Michael Leviten
  • Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
    Patent number: 9279018
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 8, 2016
    Assignee: LABRYS BIOLOGICS, INC.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • METHODS OF TREATMENT FOR NEUROMYELITIS OPTICA
    Publication number: 20160053023
    Abstract: The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating neuromyelitis optica (NMO) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 25, 2016
    Inventors: Arnon Rosenthal, Michael Leviten, Alan S. Verkman
  • Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
    Patent number: 9266951
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: February 23, 2016
    Assignee: LABRYS BIOLOGICS, INC.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME
    Publication number: 20150361173
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME
    Publication number: 20150361171
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME
    Publication number: 20150361172
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Anti-NGF antibodies and methods using same
    Patent number: 9212222
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 15, 2015
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Jaume Pons, Arnon Rosenthal
  • ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME
    Publication number: 20150291690
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: May 21, 2015
    Publication date: October 15, 2015
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
    Patent number: 9115194
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: August 25, 2015
    Assignee: Labrys Biologics, Inc.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • ANTI-NGF ANTIBODIES AND METHODS USING SAME
    Publication number: 20150050286
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Application
    Filed: November 22, 2011
    Publication date: February 19, 2015
    Inventors: JAUME PONS, ARNON ROSENTHAL
  • ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME
    Publication number: 20150050267
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: April 14, 2014
    Publication date: February 19, 2015
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • METHODS OF TREATING VASOMOTOR SYMPTOMS USING ANTIBODIES
    Publication number: 20140147438
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Application
    Filed: November 21, 2013
    Publication date: May 29, 2014
    Applicant: LABRYS BIOLOGICS, INC.
    Inventors: JOERG ZELLER, KRISTIAN T. POULSEN, YASMINA NOUBIA ABDICHE, JAUME PONS, SIERRA JONES COLLIER, ARNON ROSENTHAL
  • Methods of treating vasomotor symptoms using antibodies
    Patent number: 8734802
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 27, 2014
    Assignee: Labrys Biologics, Inc.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • METHODS FOR TREATING OSTEOARTHRITIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME
    Publication number: 20140017235
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Application
    Filed: July 19, 2013
    Publication date: January 16, 2014
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: ARNON ROSENTHAL, DAVID LOUIS SHELTON, PATRICIA ANN WALICKE
  • Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
    Patent number: 8597649
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: December 3, 2013
    Assignee: Labrys Biologics, Inc.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
  • Treatment of interstitial cystitis
    Patent number: 8591898
    Abstract: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: November 26, 2013
    Assignee: Pfizer Limited
    Inventors: Ian William Mills, Stephen Charles Phillips, Arnon Rosenthal, David Peter Scholfield, David Louis Shelton
  • Methods of using anti-CGRP antagonist antibodies
    Patent number: 8586045
    Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 19, 2013
    Assignee: Labrys Biologics, Inc.
    Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Lee Jones Collier, Arnon Rosenthal
  • METHODS FOR TREATING OSTEOARTHRITIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME
    Publication number: 20130302325
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 14, 2013
    Inventors: ARNON ROSENTHAL, DAVID LOUIS SHELTON, PATRICIA ANN WALICKE